PND130 TREATMENT PATTERNS, HEALTH RESOURCES CONSUMPTION AND COSTS OF PATIENTS WITH MIGRAINE IN AN ITALIAN REAL-WORLD SETTING

To describe demographic and clinical characteristics of migraineurs with at least one migraine prophylactic therapy,analyse therapeutic pathways and drug-utilization and evaluate health resource consumptions and costs for the Italian Health System. A retrospective study on Italian administrative databases from two Regions and three Local Health Units. Patients (≥18 years old) with at least one hospital discharge with a diagnosis for migraine (ICD-9-CM-code: 346), or one prescription of at least one specific drugs for migraine (ATC-code: N02C), or one access to ER for migraine from 01/01/2010 to 31/12/2016 (study period) were included, only if having one migraine prophylactic therapy between 01/01/2011 and 31/12/2015 (enrollment period). Index date (ID) was first date of last migraine prophylactic therapy during enrollment period. Patients were characterized the year before ID and follow-up period lasted one year after ID. Out of 166,362 migraineurs considered, 32,794 (mean age 45.9±13.9, 19.2% male)received migraine prophylaxis. Among them, 31,629 were with just one prophylactic therapy at ID: 51.2% presented antidepressant, 28.1% antiepileptics, 12.4% beta-blockers, 0.5% botulinum toxin and 7.8% other migraine preparations. In this population, 85.4% of patients didn’t have previous failed therapies, while 14.6% had at least one or more previous failed therapies during enrollment period. During follow-up, 5% of patients underwent therapeutic switch (17.3% with two or more failed therapies, 74.4% with one failed therapy and 8.3% without previous failure). Mean annual expenditure for all migraineurs in prophylaxis was 1,193.64€ during characterization and 1,303.86€ during follow-up periods. This study describes migraine’s demography, drug-utilization and healthcare resource consumptions. However, the usage of administrative databases doesn’t allow to grab out of pocket therapies costs, which remain a burden for patients. Moreover, the limited time horizon can underestimate the burden of a disease in which patients do different treatment cycles over time.